10-Q: Atossa Therapeutics Q2 Loss Widens Amid R&D Boost

Atossa Therapeutics reported an increased net loss in Q2 2025 due to higher research and development expenses, while advancing its lead breast cancer drug candidate, (Z)-endoxifen, through multiple clinical trials.

Summary

• Net loss for the six months ended June 30, 2025, increased to $15.1 million from $11.9 million in the same period of 2024.
• Cash used in operating activities for the six months ended June 30, 2025, was $13.2 million, up from $9.2 million in 2024.
• Cash and cash equivalents stood at $57.9 million as of June 30, 2025, down from $71.1 million at December 31, 2024.
• Total operating expenses rose to $16.5 million for the six months ended June 30, 2025, a $2.4 million increase from $14.1 million in 2024, primarily driven by a 32% increase in R&D expenses.
• The company is advancing its lead drug candidate, oral (Z)-endoxifen, for metastatic breast cancer, ductal carcinoma in situ (DCIS), and neoadjuvant treatment of breast cancer.
• Positive feedback was received from the FDA for the proposed dose optimization trial of (Z)-endoxifen in metastatic breast cancer, with an IND submission targeted for Q4 2025.
• Phase 2 Karisma-(Z)-endoxifen study for mammographic breast density (MBD) showed significant MBD reduction (17.3% for 1mg dose, 23.5% for 2mg dose) with a favorable safety profile for the 1mg dose.
• The company is not in compliance with Nasdaq's minimum bid price rule ($1.00) and has until August 20, 2025, to regain compliance.
• A $1.5 million liability was recorded for potential Australian R&D tax rebate disqualification.

Sentiment

Score: 4

Explanation: While there's clinical progress and a strategic focus, the increased losses, cash burn, Nasdaq non-compliance, and patent challenges present significant financial and operational headwinds, indicating a cautious outlook.

Positives

• Advancement of oral (Z)-endoxifen into multiple clinical programs for various breast cancer indications.
• Positive written feedback from the FDA on the proposed dose optimization trial for (Z)-endoxifen in metastatic breast cancer, paving the way for a Q4 2025 IND submission.
• Phase 2 Karisma-(Z)-endoxifen study demonstrated significant reduction in mammographic breast density (17.3% for 1mg dose, 23.5% for 2mg dose) with the 1mg dose showing no significant differences in adverse events compared to placebo.
• Updated results from the I-SPY 2 EOP study showed 95% participant completion, median Ki-67 reduction from 10.5% to 5% by Week 3, and significant tumor volume and diameter reduction, with (Z)-endoxifen being well tolerated.
• Management believes current cash and cash equivalents of $57.9 million are sufficient to finance operations for at least one year.
• The company holds patent protection for its proprietary (Z)-endoxifen through at least November 17, 2038, with 6 U.S. and 10 international patents granted and 128 applications pending.

Negatives

• Net loss increased to $15.1 million for the six months ended June 30, 2025, compared to $11.9 million for the same period in 2024.
• Cash used in operating activities increased to $13.2 million for the six months ended June 30, 2025, from $9.2 million in 2024.
• Cash and cash equivalents decreased to $57.9 million as of June 30, 2025, from $71.1 million at December 31, 2024.
• The company is not in compliance with Nasdaq Listing Rule 5550(a)(2) due to its common stock failing to maintain a minimum closing bid price of $1.00 for 30 consecutive business days.
• A $1.5 million liability was recorded for potential disqualification of Australian R&D tax rebates, indicating uncertainty regarding the sustainability of the full tax position under audit.
• The 2 mg dose of (Z)-endoxifen in the MBD study was associated with higher rates of hot flashes, night sweats, and vaginal discharge.
• FDA and Swedish Medical Products Agency input suggests MBD reduction alone may not be an approvable indication without demonstrating breast cancer incidence reduction.
• One of the company's issued patents (U.S. Patent No. 11,572,334) was found unpatentable by the PTAB on January 29, 2025.
• Two additional patents (U.S. Patent No. 12,071,391 and U.S. Patent No. 11,261,151) are currently being challenged by Intas Pharmaceuticals Ltd. through PGR and IPR petitions.

Risks

• History of operating losses and expectation to continue incurring losses in the future.
• Lack of established ongoing revenue sources sufficient to cover operating costs and continue as a going concern.
• Need to raise substantial additional capital in the future, with no assurance of availability or acceptable terms, potentially leading to dilution or curtailment of business plans.
• Risk that products may never achieve significant commercial market acceptance.
• Inability to establish sales, marketing, and commercial supply capabilities.
• Dependence on the services of the Chief Executive Officer, Steven C. Quay, and the adverse impact of his loss.
• Acquisitions, collaborations, licenses, and investments in other businesses may not yield expected benefits, as evidenced by a $1.7 million impairment charge related to an investment in Dynamic Cell Therapies, Inc. (DCT) in 2024.
• Difficulty in locating, attracting, and retaining experienced and qualified personnel, leading to increased employee-related costs.
• Clinical trials may take longer than expected, fail to demonstrate efficacy and safety, or preliminary data may differ from final results.
• Failure to obtain or maintain regulatory approvals from the FDA and foreign regulatory bodies.
• Patient deaths or adverse outcomes in clinical trials, even if unrelated to drugs, could negatively impact the business.
• Heavy reliance on third-party service providers for manufacturing, testing, supply chain, and clinical trial activities, with risks of failure, delay, or non-compliance.
• Exposure to possible litigation and product liability claims, which may not be fully covered by insurance.
• Risks associated with the deployment of Artificial Intelligence (AI) in product candidates, including flawed results, increased costs, and public acceptance issues.
• Business disruptions from natural disasters, severe weather, pandemics, or geopolitical tensions could harm revenue and financial condition.
• Cash held at financial institutions often exceeds federally-insured limits, posing a risk of loss in case of bank failure.
• Ability to use net operating loss carryforwards (NOLs) and research tax credits (R&D credits) may be limited or restricted due to ownership changes.
• Risk of losing the ability to operate in Australia or benefit from R&D tax rebates, potentially requiring additional changes in estimates beyond the $1.5 million liability already recorded.
• Inability to protect proprietary technology, including challenges to patents (e.g., PTAB proceedings by Intas Pharmaceuticals Ltd. invalidating one patent and challenging two others).
• Changes in U.S. patent law could diminish the value of patents.
• Inability to protect intellectual property rights throughout the world, particularly in countries with weaker IP laws.
• Current patent portfolio may not include all necessary rights, and future licenses may not be available on reasonable terms.
• Third-party claims alleging intellectual property infringement could prevent or delay drug development.
• Risk of employees, consultants, or contractors wrongfully using or disclosing confidential information of third parties.
• Inability to adequately prevent disclosure of trade secrets and other proprietary information.
• Legislative or regulatory reforms may increase difficulty and cost of obtaining approvals.
• Disruptions at the FDA and other government agencies could negatively affect regulatory review.
• Inadvertent or unintentional failure to comply with complex government regulations concerning patient privacy and medical records (HIPAA, GDPR, UK GDPR).
• Significant disruptions in information technology systems or data security breaches.
• Failure to comply with federal and state laws related to claims submission (Medicare, Medicaid).
• Significant competition from other biotechnology and pharmaceutical companies, including those using emerging AI technologies.
• Risk of employee and third-party misconduct, including non-compliance with regulatory standards.
• Risks associated with handling hazardous and dangerous materials in R&D activities.
• Risk of delisting from Nasdaq due to non-compliance with the minimum bid price requirement.
• Potential for substantial dilution from future sales of common stock.
• Volatility of the common stock trading price.
• No anticipated dividends in the future.
• Ownership of common stock may become concentrated, influencing management and operations.
• Inability to implement and maintain effective internal control over financial reporting.
• Requirements of being a public company may strain resources and result in litigation.
• Anti-takeover provisions in governing documents and Delaware law could delay or prevent a change in control.
• Exclusive forum provision could limit stockholders' ability to obtain a favorable judicial forum.
• Impact of securities or industry analysts' research on stock price and trading volume.

Future Outlook

The company expects to incur ongoing operating losses for the foreseeable future as it continues to develop its therapeutic programs and clinical studies. Future funding requirements depend on manufacturing costs, clinical trial expenses, intellectual property costs, and potential acquisitions. Management believes current cash is sufficient for at least the next 12 months but plans to raise additional capital through equity offerings, debt financings, or collaborations. The company is targeting an Investigational New Drug (IND) submission for (Z)-endoxifen in metastatic breast cancer for the fourth quarter of 2025.

Management Comments

• "Management believes its currently available cash and cash equivalents will be sufficient to finance the Company's operations for at least one year from the date these Condensed Consolidated Financial Statements are issued."
• "The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity offerings, debt financings or other sources, including potential corporate collaborations, licenses and other similar arrangements."
• "In early 2025, we made a strategic decision to pursue a metastatic breast cancer indication for our lead program, (Z)-endoxifen. We believe that this approach may offer a more streamlined regulatory pathway to deliver (Z)-endoxifen to patients with urgent unmet medical needs as the current treatment options for metastatic breast cancer often provides limited durability of response and substantial side effects."
• "We have received positive written feedback from the FDA regarding our proposed dose optimization trial for (Z)-endoxifen in patients with ER+/HER2metastatic breast cancer affirming key elements of Atossa's clinical development plan and paving the way for a potential IND submission targeted for the fourth quarter of 2025."
• "We intend to vigorously contest the 391 PGR Petition and the 151 IPR Petition and believe that the Patents were properly granted and include valid and enforceable claims."

Industry Context

The company operates in the highly competitive and rapidly evolving biotechnology and pharmaceutical industry, specifically focusing on oncology and breast cancer. Its strategy to pursue a metastatic breast cancer indication for (Z)-endoxifen aligns with addressing significant unmet medical needs where current treatments offer limited durability and substantial side effects. The industry faces challenges including high R&D costs, stringent regulatory approvals, and intense competition from larger pharmaceutical companies and those leveraging emerging AI technologies for drug discovery. The company's patent disputes highlight the common intellectual property challenges in this sector.

Comparison to Industry Standards

• The company's focus on (Z)-endoxifen as a Selective Estrogen Receptor Modulator (SERM) places it in competition with established SERMs like Tamoxifen, but its proprietary formulation aims for improved efficacy or safety profiles.
• The I-SPY 2 EOP study, a collaborative effort with major cancer research centers, QLHC, FDA, and FNIH, is a recognized platform for evaluating novel breast cancer therapies, indicating the company's participation in a high-standard research network.
• The reported median Ki-67 reduction from 10.5% to 5% by Week 3 and 77.7% decrease in median functional tumor volume in the I-SPY 2 EOP study are significant biological responses that would be compared against other neoadjuvant therapies for ER+/HER2breast cancer, such as standard endocrine therapies or CDK4/6 inhibitors like Eli Lilly's Verzenio (abemaciclib), which the company is now combining with (Z)-endoxifen in a new study arm.
• The challenge from Intas Pharmaceuticals Ltd. regarding patent validity is a common occurrence in the pharmaceutical industry, where generic drug manufacturers often challenge patents of branded drugs to enable market entry.

Legal Proceedings

• Intas Pharmaceuticals Ltd. filed a Petition for Post Grant Review (PGR) on April 3, 2025, with the USPTO Patent Trial and Appeal Board (PTAB) seeking to invalidate U.S. Patent No. 12,071,391, titled "Methods for Making and Using Endoxifen," on grounds of anticipation, obviousness, lack of written description, and lack of enablement. A decision is expected by September 8, 2025.
• Intas Pharmaceuticals Ltd. also filed a Petition for Inter Partes Review (IPR) on April 3, 2025, with the USPTO PTAB seeking to invalidate U.S. Patent No. 11,261,151, titled "Methods for Making and Using Endoxifen," on grounds of anticipation and obviousness. A decision is expected by September 8, 2025.
• On January 29, 2025, the PTAB issued a final written decision finding all claims of U.S. Patent No. 11,572,334, titled "Methods for Making and Using Endoxifen," unpatentable, following a petition filed by Intas Pharmaceuticals Ltd. on August 18, 2023.
• The company intends to vigorously contest the ongoing PGR and IPR petitions, believing the patents were properly granted and include valid and enforceable claims.
• The company is subject to other legal proceedings and claims arising in the ordinary course of business, which are not believed to have a material effect individually or in aggregate.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity raises; risk of stock price volatility and delisting from Nasdaq due to non-compliance with minimum bid price rule; impact from ongoing patent litigation and R&D tax rebate liability.
• Employees: Increased R&D compensation expenses due to headcount increases; potential for stock-based compensation; risk of increased employee-related costs due to market changes and inflation.
• Customers (Future Patients): Potential for new treatment options for breast cancer patients if (Z)-endoxifen successfully completes clinical trials and gains regulatory approval; strategic focus on metastatic breast cancer aims to address urgent unmet medical needs.
• Suppliers/CROs: Continued reliance on third-party service providers for manufacturing, testing, and clinical trial activities, indicating ongoing business for these partners.
• Creditors: Increased net losses and cash burn could impact future creditworthiness, though current cash position is deemed sufficient for 12 months.

Next Steps

• Targeted IND submission for (Z)-endoxifen in metastatic breast cancer in Q4 2025.
• Decision expected from the PTAB by September 8, 2025, regarding the 391 PGR Petition and 151 IPR Petition challenging two of the company's patents.
• Regain compliance with Nasdaq Listing Rule 5550(a)(2) by August 20, 2025, by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
• Continue enrollment in the Phase 2 DCIS: RECAST study for (Z)-endoxifen.
• Continue enrollment in the I-SPY 2 EOP study arm evaluating (Z)-endoxifen in combination with abemaciclib.
• Potentially conduct additional studies of (Z)-endoxifen to assess its correlation with breast cancer risk and/or reduction in incidence of new breast cancers, following FDA/Swedish MPA input on MBD reduction.
• Continue to fund operations through potential public or private equity offerings, debt financings, or corporate collaborations.

Key Dates

Recommendation

The company is a clinical-stage biopharmaceutical firm with promising drug candidates in breast cancer, particularly (Z)-endoxifen, showing positive early clinical results and strategic FDA engagement for metastatic breast cancer. This indicates long-term potential. However, the company faces significant near-term challenges including widening net losses, increased cash burn, and a critical Nasdaq non-compliance issue that could lead to delisting. Furthermore, recent patent invalidations and ongoing challenges to key intellectual property create substantial uncertainty regarding future market exclusivity. While the clinical progress is encouraging, the financial and legal headwinds warrant a "hold" recommendation, suggesting investors monitor the resolution of the Nasdaq compliance, the outcome of patent disputes, and the company's ability to secure additional funding without excessive dilution before considering further investment.

Keywords

Atossa Therapeutics, ATOS, Biopharmaceutical, Oncology, Breast Cancer, (Z)-endoxifen, Clinical Trials, Drug Development, SEC Filing, 10-Q, Financial Results, Nasdaq Compliance, Patent Litigation, Mammographic Breast Density, Ductal Carcinoma In Situ, Neoadjuvant Therapy, SERM, Pharmaceuticals, Biotech